Drug intelligence / Profile preview

PA-MSHA + capecitabine

Development stage: Preclinical
Lead developer: Beijing Wanter Bio-pharmaceutical
Modality: Small Molecules
Administration: Intramuscular, Oral

Overview

PA-MSHA + capecitabine is a combination therapy consisting of Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) and capecitabine. PA-MSHA is a genetically modified and inactivated form of Pseudomonas aeruginosa with mannose-sensitive hemagglutinin that has immunomodulatory and antitumor properties. It functions by triggering the TLR5/NF-κB signaling pathway in antigen-presenting cells, promoting M1 macrophage polarization, enhancing T cell activation, and inducing apoptosis in cancer cells. Capecitabine is an oral fluoropyrimidine antineoplastic agent that is converted to 5-fluorouracil in tumor tissues.

Targets

TLR5TS (Thymidylate synthase)

Beyond the preview

Go deeper on PA-MSHA + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PA-MSHA + capecitabine.

Explore the full profile